Stockwinners Market Radar for January 30, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:20 EST Cathie Wood's ARK Investment bought 77.4K shares of Roku today

20:19 EST Cathie Wood's ARK Investment bought 373.5K shares of Teladoc today

18:28 EST Groupon to cut 500 jobs as part of cost savings plan - In a regulatory 8-K filing, the company states: "On January 25, 2023, the Board of Directors of Groupon approved the second phase of the Company's multi-phase restructuring plan, which is part of the Company's comprehensive cost savings plan, announced in August 2022. This second phase is expected to include an overall reduction of approximately 500 positions globally, with the majority of these reductions expected to occur by the end of the second quarter of 2023. In connection with the 2022 Restructuring Plan, the Company has incurred total pretax charges of approximately $9.6 million since the inception of the 2022 Restructuring Plan through December 31, 2022. In connection with the actions under the second phase, the Company expects to record total pre-tax charges of between $10.0 million and $20.0 million. The majority of these pre-tax charges are expected to be paid in cash and will primarily relate to employee severance and compensation benefits, with an immaterial amount of charges related to other exit costs. The payroll actions under the second phase of the 2022 Restructuring Plan are estimated to result in approximately $70.0 million in annualized cost savings. The Company also intends to implement other non-payroll actions outlined within the 2022 Cost Savings Plan, including reducing technology, software and certain professional services costs. These actions are expected to create an additional $30.0 million in annualized cost savings."

18:02 EST Director of Greene County Bancorp Nelson sells 4,874 shares of company stock - Director of Greene County Bancorp Stephen Nelson sold 4,874 shares of company stock at $47 per share on January 27, for a total transaction amount of $229,07.

17:43 EST International General Insurance repurchased 2.27M in common stock - International General Insurance announced that it has repurchased 2,271,775 common shares in a privately-negotiated transaction. The shares were repurchased at a price of $8.60 per share, for a total cost of approximately $19.5M. The Company has approximately 2.4 million common shares remaining under its current common share repurchase authorization of up to 5 million shares, approved by the Board of Directors in May 2022.

17:24 EST Aecom awarded $239M Navy contract - Aecom was awarded a $239M cost-plus-fixed-fee, indefinite-delivery/indefinite-quantity contract for architect-engineer services for environmental restoration projects, including technical and engineering services, field investigation services, laboratory testing and related services for all stages of the Comprehensive Environmental Response, Compensation, and Liability Act, or CERCLA, process. Work will be performed at various locations within the Naval Facilities Engineering Systems Command, or NAVFAC, Pacific area of responsibility, and may also include locations within NAVFAC Southwest, NAVFAC Northwest, or anywhere outside the NAVFAC Pacific area of responsibility, as required by the government. Work is expected to be completed by January 2028. Immediately following award, a task order will be issued in the amount of the minimum guarantee of $5,000 using fiscal 2023 environmental restoration funds, which will expire at the end of the current fiscal year. This contract was competitively procured under full and open competition via the System for Award Management website, with one offer received. The Naval Facilities Engineering Systems Command is the contracting activity.

17:19 EST German American Bancorp raises quarterly dividend 9% to 25c per share - German American Bancorp announced a 9% increase in the level of its regular quarterly cash dividend, as its Board of Directors declared a regular quarterly cash dividend of 25c per share, which will be payable on February 20, 2023 to shareholders of record as of February 10, 2023.

17:18 EST Agree Realty to replace Store Capital in S&P 400 at open on 2/6 - Store Capital is being acquired in a transaction expected to be completed soon pending final conditions.

17:01 EST Dollar General CFO John Garratt to retire - Dollar General announced John Garratt's intent to retire from his position as president and CFO effective June 2. Taking into account its robust succession plans, Dollar General will evaluate options for its next CFO and is not currently conducting an external search.

16:57 EST Meridian Bank raises dividend to 25c from 20c - On January 26, the Board of Directors declared a quarterly cash dividend of 25c per common share, payable February 21 to shareholders of record as of February 14.

16:38 EST PointsBet, NBC Universal amend media services agreement and extend partnership - PointsBet announced today that its wholly owned subsidiary, PointsBet, and NBCUniversal Media, a subsidiary of Comcast (CMCSA), have agreed to amend the media services agreement dated August 27, 2020. See market announcement dated August 28 for details regarding the original agreement. Under the amended agreement, the remaining committed marketing spend for Years 3 to 5 of the original agreement will be invested over an additional two years, now representing years 3 to 7, thus reducing the average annual marketing spend to match PointsBet's optimum desired level of investment under its more localised, targeted strategy. PointsBet maintains preferred pricing benefits and integration exclusivity in the sports betting category at a local and regional level, including across NBCU's Regional Sports Networks. PointsBet also maintains its online casino integration exclusivity at a local, regional and national level. PointsBet has relinquished sports betting integration exclusivity over NBCUniversal's national media assets, however PointsBet retains a 'second look' for all national NBCUniversal assets. NBCUniversal will be permitted to appoint one additional 'Official Sports Betting Partner' of NBC Sports. As part of the amended agreement the portfolio of available assets for investment is expanded to now also include Peacock, sports programming on USA Network and CNBC digital. In addition, the amended agreement allows PointsBet to more heavily utilize Comcast's EffecTV platform. With an estimated reach of 96 million US adults, EffecTV allows PointsBet to target audiences with postcode level precision across linear TV, streaming and video on demand. The total committed marketing spend for the remaining 5 years is $294M, with $25M of this commitment having already been paid as at December 31, 2022. The total commitment for the current year is $50M. Should the options issued to NBCUniversal at the time of the original agreement not be exercised, instead of a lump sum repayment of the option premium value by the company at the end of Year 5, this amount will be applied to make increased payments for Media Services across Years 6 and 7. Where this is the case, the total cash commitment over the remaining five years of the term, applied largely on an equal annual basis, will be $270.4M, with the balance to be covered by the remaining value of the shares previously issued to NBCUniversal. PointsBet expects its U.S. marketing expense for FY23 to be circa $90M, down from $118M in FY22.

16:31 EST Novo Integrated Sciences announces Nasdaq listing non-compliance notice - Novo Integrated Sciences reported that it received a notice on January 25, 2023 from the Listing Qualifications Department of The Nasdaq Stock Market LLC advising the Company that it was not in compliance with Nasdaq's continued listing requirements under Nasdaq Listing Rule 5250(c)(1) as a result of its failure to timely file its Annual Report on Form 10-K for the fiscal year ended August 31, 2022 and its Quarterly Report on Form 10-Q for the fiscal quarter ended November 30, 2022. The Company previously disclosed that it received a notice from Nasdaq on December 15, 2022 advising the Company that it was not in compliance with Rule 5250(c)(1) as a result of its failure to timely file the Form 10-K.

16:24 EST Simply Good Foods says Geoff Tanner, named COO, CEO-elect of company - The Simply Good Foods (SMPL) announced a CEO succession plan. Geoff Tanner, formerly Chief Commercial and Marketing Officer at The J.M. Smucker Company (SJM), has been named President, Chief Operating Officer and CEO Elect and a member of the Simply Good Foods Board of Directors, effective April 3 . Mr. Tanner will subsequently succeed Joseph E. Scalzo as Chief Executive Officer on July 7, in connection with Mr. Scalzo's sixth anniversary as CEO of the Company. At the time of the CEO succession, Mr. Scalzo will be appointed as Executive Vice Chair of the Board and will serve in this role through August 31, 2024, the last day of the Company's fiscal year 2024. Mr. Scalzo is expected to continue to serve as a director thereafter. Upon Mr. Scalzo's appointment as Executive Vice Chair, David J. West will step down from the position of Vice Chair of the Board, but is expected to continue to serve as an independent director of the Company.

16:22 EST Albemarle launches Ketjen, a wholly owned subsidiary - Albemarle announced the official brand launch of Ketjen, its wholly owned subsidiary that crafts tailored, advanced catalyst solutions for the petrochemical, refining and specialty chemicals industries. The company shared the new name of its catalysts business in November 2022 after announcing plans to operate the business as a subsidiary. Headquartered in Houston, Texas, Ketjen will collaborate with customers in the petrochemical, refining and specialty chemical industries across three divisions, Fluidized Catalytic Cracking, Clean Fuels and Hydroprocessing Catalysts, and Performance Catalyst & Curative Solutions. Albemarle's existing advanced catalyst solutions team will lead Ketjen operations.

16:19 EST Woodward boosts dividend 16% to 22c per share - Woodward announced that its Board of Directors approved a dividend of 22c per share, up from the prior quarter's dividend of 19c per share. The dividend will be payable on March 7 for stockholders of record as of February 21 .

16:17 EST Whirlpool jumps 4% to $159.59 after FY23 guidance beats estimates

16:15 EST Alexandria Real Estate reports Q4 same property net operating growth 4.7% - Reports same property net operating income growth: 4.7% for Q4, representing the third-highest growth in Company history; 6.6% for 2022 over 2021, with both increases representing the highest growth in Company history. FY22 same property growth outperformed our 10-year averages of 3.6% and 6.7% (cash basis) as a result of an increase in same property occupancy of 100 bps and early lease renewals that commenced in late 2021/early 2022.

16:12 EST Graco sees FY23 revenue growth up low single digits - Consensus $2.2B. The company states: "As we head into 2023, order rates and business tempo will be closely monitored and we are cautiously optimistic that Graco will see sales growth on a full-year basis. We are initiating a revenue outlook for the year of low single-digit growth on an organic, constant currency. Our core growth strategies of developing new products, expanding distribution, seeking adjacent markets and pursuing strategic acquisitions will help our growth prospects this year and in the future."

16:09 EST Transcat says gross margin improvement to continue - The company states: "We are pleased with the impressive growth across all of our business channels including double-digit organic Service growth in our fiscal third quarter. We expect our unique value proposition to continue to drive a sustainable competitive advantage in the highly regulated markets that we serve, particularly the Life Science and Aerospace and Defense markets. We are confident our work around differentiation, which includes Nexa's unique service tracks, data analytic capabilities and consulting platform, will foster continued consistent organic revenue growth. Driven by recurring revenue streams and high levels of regulation, we expect our Service segment to outperform through various economic cycles. Our acquisition pipeline is very active. Acquisitions, which have generated compelling returns throughout the fiscal year, will continue to be an important component of Service growth. In addition, in both the quarter and year ahead, we expect organic Service revenue growth to remain in the high-single digit range. We also expect gross margin improvement to continue as a by-product of both growth and successful execution of various ongoing productivity enhancement programs."

16:07 EST Whirlpool sees FY23 cash from operating activities $1.4B, free cash flow $800M

16:06 EST Matinas BioPharma provides business update, cash position - The company's preliminary, unaudited estimate of cash, cash equivalents and marketable securities at December 31, 2022, is approximately $28.8M, subject to completion of the audit of the company's consolidated financial statements for the year ended December 31, 2022. This compares to $49.9M at December 31, 2021. Based on current projections, the company believes that cash on hand is sufficient to fund planned operations into the second quarter of 2024. "In 2022 we successfully demonstrated that MAT2203, our lead asset based on our lipid nanocrystal (LNC) delivery platform, could safely and effectively deliver unprecedented survival outcomes, with an oral therapy, for patients suffering from deadly fungal infections," commented Jerome Jabbour, CEO of Matinas. "Our success with smaller molecules increased our confidence in the platform and empowered us to focus on what we believe is the real future of medicine - the ability to safely and effectively deliver therapies that affect the genetic mechanisms underlying disease. We are striving to create an internal and external pipeline of product candidates in the nucleic acid and gene therapy space that take advantage of the unique and proprietary nature of our delivery technologies. Our ongoing collaborations with BioNTech and, recently, National Resilience, have aligned Matinas with two of the world's leading companies in the gene therapy space. These collaborations were designed to accelerate the overall development of our LNC platform and maximize the value we can obtain from third parties while providing us with critical data and information necessary to establish and develop an internal pipeline of nucleic acid therapies." Jabbour added, "During these uncertain economic times, we remain cognizant of our cash resources and have chosen to prioritize those activities which we believe will create the greatest shareholder value. Through these strategic choices, we have extended our cash runway into the second quarter of 2024, well beyond potential value-creating catalysts and near-term opportunities for non-dilutive funding from LNC partners and/or BARDA. We could not be more excited about what we are building at Matinas, and we believe that 2023 will be a great year for the Company and its shareholders."

16:05 EST Logitech names Charles Boynton CFO - Logitech announced that Charles 'Chuck' Boynton will be joining the company as chief financial officer of Logitech, effective on February 6, 2023. In addition, Prakash Arunkundrum has been named chief operating officer. "I am excited to welcome Chuck to Logitech. As a proven global CFO, with established experience in consumer and B2B collaboration technology, he will be a great addition to help drive our long-term growth strategy," said Bracken Darrell, Logitech president and chief executive officer. "I also want to thank Nate for his leadership through an incredible period of Logitech's history." As CFO and member of Logitech's Group Management Team, Boynton will be responsible for the company's financial strategies and worldwide finance organization. He will manage a multi-billion US dollar P&L, as well as tax, treasury, accounting, financial planning and analysis functions. Additionally, he will drive communication with an international base of shareholders trading Logitech shares on the SIX Swiss Exchange and the Nasdaq Global Select Market.

14:17 EST Instagram launches Notes in Europe and Japan - Adam Mosseri, head of Meta's Instagram, said the platform's Notes feature is now available in Europe and Japan. The feature, which allows users to submit short posts of up to 60 characters that just include text and emojis, initially rolled out in December outside of Europe and Japan. Reference Link

13:36 EST Jana Care, Roche collaborate to develop, distribute blood testing platform - Jana Care, Inc. an early stage at-home In Vitro Diagnostics company, and Roche Diagnostics announced a collaboration agreement for its digitally connected, blood testing platform to enable patients to self-administer critical blood tests at-home and clinicians to review the test results remotely. Initially focused on monitoring the progression of chronic kidney disease and heart failure, the platform is designed to overcome distance and socioeconomic hurdles impeding adequate and timely detection and monitoring of disease progression and risk management. "The addition of a world-class strategic partner such as Roche to our existing development relationships provides strong support to the company's momentum in bringing this groundbreaking technology to market," said Anh Hoang-Lindsay, Chief Executive Officer of Jana Care. "The need for improving real point-of-care testing is critical as innovation needs to keep pace with our more decentralized healthcare model."

12:55 EST Freightos Ltd trading resumes

12:45 EST Freightos Ltd trading halted, volatility trading pause

12:14 EST Medtronic recalls Hemodialysis Catheters for leaks, FDA says - Medtronic is recalling 22,763 Mahurkar Acute Dual Lumen High Flow Hemodialysis Catheters due to a potential catheter hub defect that may cause leaks across the catheter's tubes, the FDA announced. During treatment, the leak could result in mixing of the arterial and venous blood, lead to increased recirculation and poor dialysis, or cause the development of blood clots in the blood vessels, the agency said in a statement. There have been two injuries reported related to this issue and no reports of death. The FDA has identified this as a Class I recall, the most serious type of recall. Use of these devices may cause serious injuries or death, it said. Reference Link

12:00 EST Yalla falls -10.1% - Yalla is down -10.1%, or -55c to $4.87.

12:00 EST FiscalNote falls -27.1% - FiscalNote is down -27.1%, or -$1.37 to $3.69.

12:00 EST MiX Telematics rises 10.9% - MiX Telematics is up 10.9%, or 80c to $8.17.

11:44 EST Johnson & Johnson falls after court rejects bankruptcy plan for talc lawsuits - Shares of Johnson & Johnson have moved lower in late morning trading after the United States Court of Appeals for the Third Circuit court rejected the company's plan to use a legal strategy to push about 38,000 talc lawsuits into bankruptcy court. In a ruling posted to the court's site, the circuit judges wrote: "These cases came to be heard on the record before the United States Bankruptcy Court for the District of New Jersey and were argued on September 19, 2022. On consideration whereof, it is ordered and adjudged by this Court that the order of the Bankruptcy Court entered March 2, 2022 is reversed and the case is remanded with the instruction to dismiss Appellee's Chapter 11 petition. The order of the Bankruptcy Court entered March 4, 2022 is vacated as moot." In Monday morning trading following news of the appeals court ruling, shares of Johnson & Johnson are down $4.46, or 3%, to $163.76.

11:18 EST GM Defense, American Rheinmetall win contract for U.S. Army's CTT Program - American Rheinmetall Vehicles and GM Defense have won a contract for the first phase of the U.S. Army's Common Tactical Truck Program. The aim of the multi-phased program is to replace the Army's family of heavy tactical trucks with production of up to 40,000 trucks valued at up to $14B.

10:24 EST Greenwave Technology expects optimal market conditions in 2023 - Greenwave Technology Solutions shares that it expects optimal market conditions for scrap metal recycling throughout 2023 and for the foreseeable future, with prices for many of Greenwave's products near record highs. As stated in the Goldman Sachs Research Report 2023 Commodity Outlook: An Underinvested Supercycle dated December 14, 2022, "From a fundamental perspective, the setup for most commodities next year is more bullish than it has been at any point since we first highlighted the supercycle in October 2020." Driven by depleted global inventories, lack of capex investments to create new supply sources, and increasing demand from China, it is widely expected that commodity prices will rise in 2023. Over the past twelve months, Greenwave has invested over $10M in its scrap metal processing infrastructure, which is expected to double the Company's scrap metal processing capacity and significantly increase its margins, once all systems are online. Greenwave's second automotive shredder and downstream processing system are on schedule to commence operations during the first quarter of 2023, resulting in the Company having the infrastructure to economically support significant expansion.

10:07 EST Armada Acquisition Corp I trading halted, volatility trading pause

10:00 EST Tencent Music falls -8.2% - Tencent Music is down -8.2%, or -71c to $7.96.

10:00 EST FiscalNote falls -20.9% - FiscalNote is down -20.9%, or -$1.06 to $4.00.

10:00 EST ProShares UltraShort Bloomberg Natural Gas rises 10.6% - ProShares UltraShort Bloomberg Natural Gas is up 10.6%, or $5.11 to $53.34.

09:59 EST TerrAscend closes on acquisition of Allegany Medical Marijuana Dispensary - TerrAscend announced the closing of its previously announced acquisition of Allegany Medical Marijuana Dispensary, a medical dispensary in Cumberland, Maryland. Under the terms of the agreement, TerrAscend has acquired a 100% equity interest in AMMD for total consideration of $10M in cash, in addition to entering into a long-term lease with the option to purchase the real estate. This medical dispensary, located in Northwest Maryland within six miles of both the West Virginia and Pennsylvania borders, generated net revenues in excess of $8M in 2022. In anticipation of adult use later this year, TerrAscend expects to rebrand the 10,000 square foot dispensary as The Apothecarium, the Company's award-winning retail dispensary concept. The dispensary will carry TerrAscend's full selection of high-quality branded products, including Gage, Kind Tree, Valhalla, and Wana edibles, subject to regulatory approval. TerrAscend's retail footprint now includes 32 dispensaries nationwide.

09:50 EST Carvana trading resumes

09:47 EST Vipshop falls -8.5% - Vipshop is down -8.5%, or -$1.31 to $14.13.

09:47 EST Tencent Music falls -10.0% - Tencent Music is down -10.0%, or -86c to $7.81.

09:47 EST Carvana rises 7.9% - Carvana is up 7.9%, or 61c to $8.38.

09:45 EST Carvana trading halted, volatility trading pause

09:40 EST Opthea Ltd (ADR) trading resumes

09:37 EST Tecogen appoints Abinand Rangesh as CEO - Tecogen announced the appointment of Dr. Abinand Rangesh as CEO. Dr. Rangesh is presently the CFO and a member of the Company's Board of Directors. He has been with the Company since 2016 and has held roles in various divisions including sales, business development and strategy.

09:34 EST Janus Henderson intends to vote against Ritchie Bros., IAA deal - Janus Henderson Group portfolio managers Brian Demain and Cody Wheaton sent a letter to the board of Ritchie Bros. (RBA) opposing the company's proposed takeover of IAA (IAA). The letter states in part, "We have engaged in an open dialogue with Ritchie Brothers management since the announcement of the proposed acquisition of IAA on November 7, 2022 and have valued the opportunity to express our views. Our clients have been owners of Ritchie Brothers stock continuously for over ten years. As such, we have unique insight into the history and competitive positioning of the company, as well as a long-term perspective when evaluating major strategic initiatives, such as the proposed merger with IAA. We are against the Ritchie Brothers acquisition of IAA for the following reasons: At the core, we believe the merger would introduce a level of unnecessary risk for Ritchie Brothers shareholders...We believe the deal is a distraction from the core Ritchie Brothers strategy described by management...The IAA business has been losing share over the last several years and may be structurally disadvantaged versus its main competitor, Copart...It is evident from reading the proxy that merger discussions were initiated with IAA contacting Ritchie Brothers. This calls into question the strategic rationale for the deal from the Ritchie perspective...The used car market is beginning to regress from an artificial peak in prices created by COVID coupled with supply chain issues...The combined company will take on substantial debt to complete the transaction at a time when interest rates are rising...In summary, we have significant misgivings about the strategic and financial rationale for this deal, and think the structure and timing are concerning. Based on our current understanding and the current deal terms, it is our intention to vote against the transaction. "

09:28 EST Nano Dimension rejects Murchinson request for special meeting of shareholders - Nano Dimension announced that the demand received by Murchinson and Marc Bistricer to call a special shareholder fails to comply with the requirements set forth under the Israeli Companies Law for calling such a meeting. Hence, the meeting request was rejected. The company said, "The Board of Directors of Nano Dimension is acting in accordance with the applicable laws and regulations in Israel and the United States, as well as with the Company's articles of association, in order to protect the Company and its shareholders' rights. Given Murchison's record of stock manipulations, violations of law and legal proceedings with United States regulatory authorities, the Board is committed to carefully examine any demand made by Murchinson as well as their conduct surrounding the Company in order to protect the rights of all of Nano Dimension's shareholders and for the benefit of the Company."

09:26 EST Diana Shipping announces delivery of m/v DSI Aquarius, time charter contract - Diana Shipping announced that, through a separate wholly-owned subsidiary, it has taken delivery of the m/v DSI Aquarius, a 2016 built Ultramax dry bulk vessel of 60,309 dwt. The vessel is one of nine modern Ultramax dry bulk vessels that the Company entered into an agreement to purchase in August 2022. The Company also announced that, through the same wholly-owned subsidiary, it entered into a time charter contract with Engelhart CTP Freight, at a gross charter rate of $14,200 per day, minus a 5% commission paid to third parties, for a period until minimum January 10, 2024 up to maximum March 25, 2024. The charter is expected to commence on February 1, 2023. The employment of "DSI Aquarius" is anticipated to generate approximately $4.81 million of gross revenue for the minimum scheduled period of the time charter.

09:19 EST Ocean Biomedical, Aesther announc publication of discovery data - Ocean Biomedical and Aesther Healthcare Acquisition announced the discovery of a second major anti-tumor pathway and therapeutic approach that targets CTLA-4, inhibiting the metastasis of malignant melanoma cells to the lung using a novel bispecific antibody approach. This major regulating mechanism discovery, recently published in Frontiers in Immunology, by Ocean Biomedical's Scientific Co-founder and Brown University's Emeritus Dean of Medicine and Biological Sciences, Dr. Jack A. Elias, builds on his team's prior discoveries that target Chitinase 3-like-1 and its role in inhibiting T-cell proliferation. Additionally, this promising research reveals a third anti-tumor pathway targeting T-cell co-stimulation using the inducible co-stimulator and its ligand ICOSL, and Cluster of Differentiation 28 and its ligands B7-1 and B7-2. Ocean Biomedical's novel approach to tumor suppression, focused on controlling CHI3LI, other immune checkpoint inhibitors, and T-cell co-stimulators, has potential application for tumor suppression across multiple cancer pathways. Malignant melanoma, a very serious skin cancer with a 22.5% five-year survival for patients with Stage IV disease, can metastasize to other organs. Once it has spread to other organs, it is difficult to treat - in some cases, it can spread to the lungs and result in non-small cell lung cancer, a major unmet medical need that accounts for 85% of pulmonary malignancies and affects approximately 450,000 individuals. In over 50% of affected NSCLC patients, tumors are not diagnosed until the advanced stages, with metastatic spread that precludes curative surgical resection. Recent studies of NSCLC have highlighted the effectiveness of immune checkpoint inhibitor, therapies that block cancer-proliferating proteins like CHI3L1 and help the patient's body recognize and attack cancer cells. Unfortunately, only a minority of patients respond to these therapies and the responses are often not durable. Recent studies from Ocean Biomedical have demonstrated that CHI3L1 is a critical regulator of a number of key cancer-causing pathways, highlighting its ability to inhibit tumor cell death, its inhibition of the expression of the tumor suppressors P53 and PTEN and its stimulation of the B-RAF protooncogene. Most recently Dr. Elias's research team has discovered that CHI3L1 is a "master regulator" of ICPI, including key elements of the PD-1 and CTLA4 pathways. In accord with the importance of these pathways, Ocean has also generated antibodies: a monoclonal antibody against CHI3L1, bispecific antibodies that simultaneously target CHI3L1 and PD-1, and a new bispecific antibody that simultaneously targets CHI3L1 and CTLA4. The impressive ability of these bispecific antibodies to control primary and metastatic lung cancer in murine experimental modeling systems have been discussed in detail in an earlier article in the Journal of Clinical Investigation, and this expanded approach in Frontiers in Immunology.

09:16 EST EzFill to launch EzFill NOW Program - EzFill Holdings is launching in selected Miami zip codes its EzFill NOW program, where customers can now opt for guaranteed fuel delivery within either a 30 minute or 60 minute time frame. Currently, EzFill services individual consumers directly at their residence or place of work at pre-arranged delivery windows, often at night. The EzFill NOW program enhances the Company's service offering by allowing customers a truly On-Demand feature, available through a button on the EzFill app. The program is being launched in selected Miami Beach zip codes, and will offer customers a Priority feature, with delivery within 60 minutes, or Super Priority, with delivery within 30 minutes. The program will be available to both EzFill subscribers and non-subscribers, with existing subscribers offered discounted rates.

09:14 EST ACCESSWIRE acquires Newswire, terms not disclosed - ACCESSWIRE acquired Newswire, an industry leader in press release distribution services and media technology in November 2022. This integration blends the unique assets of each brand to provide a comprehensive host of services that help companies of all sizes and industries, public and private, effectively deliver their stories to maximize the moment.

09:13 EST Gyrodyne issues letter to holder saying 'on track' for sale of properties - Gyrodyne issued the following letter to shareholders from Gary Fitlin, Gyrodyne's Chief Executive Officer. "As we start the new year, I would like to express my gratitude for your investment in Gyrodyne...Looking ahead into 2023 and beyond, I wanted to take this opportunity to provide some color on our engagement with shareholders as well as specific updates on the business ultimately, we remain on track to position the Company's properties for sale at enhanced values, distribute the maximum net asset value possible to our shareholders and dissolve. As you may know, some shareholders' concerns about the Company and our corporate governance were evident at the 2022 Annual Meeting of Shareholders. The entire Board and management team take these concerns very seriously and have been reflecting on the voting results from the meeting. In short order, we embarked on a listening tour and spoke with the vast majority of our major sharehold. We are working hard to enhance property values, liquidate and distribute proceeds and dissolve the Company, which we expect to occur by the end of 2024. We believe that our fortified balance sheet strongly positions Gyrodyne to continue executing on our corporate strategy and we will continue to focus on the pursuit of expedited entitlements and taking the necessary steps to increase the value of our operating properties. ..We are confident the steps we are taking will deliver enhanced value for our shareholders and look forward to communicating further with you in the coming months.

09:12 EST Motorsport Games announces opening of F1 Arcade - Adam Breeden has officially opened F1 Arcade, the world's first official premium F1 experiential venue, on December 12, 2022 in London at One New Change, St Pauls. The immersive state of the art F1 racing simulation experience comes with 60 motion F1 simulators, powered by the rFactor 2 racing simulation software provided by Motorsport Games, combined with exclusive F1 content, enabling guests to live the thrill of racing, complemented by a food and beverage offering created by an executive chef and expert mixologists.

09:09 EST Fortinet expands services, training offerings to further support SOC teams - Fortinet announced new security operations center, SOC, augmentation services designed to help strengthen an organization's cyber resiliency and support short-staffed teams strained by the talent shortage. In addition, as part of Fortinet's leadership efforts to help close the cyber skills gap, the Fortinet Training Institute has added initiatives across its programs to further increase access to its industry-recognized training and certifications. John Maddison, EVP of Products and CMO at Fortinet, said, "Fortinet builds ML-driven automation into all of its SOC offerings to support short-staffed teams affected by the cybersecurity skills shortage. But technology alone won't solve this issue, which is why we are dedicated to also delivering human-based SOC augmentation services to provide immediate support, while investing in an industry-leading training institute to close the cybersecurity skills gap. This combination of technology, services, and training enables SOC professionals to better protect their organizations from detection to incident recovery."

09:07 EST Metroland outsources newspaper printing to TC Transcontinental - TC Transcontinental (announced that Metroland Media Group is outsourcing to TC Transcontinental the printing of all its newspapers currently taking place at its Tempo facility in Toronto. In addition to these two daily newspapers and 49 community publications, the deal extends the current printing agreement of two daily newspapers, including the Toronto Star, and four community publications, to the end of 2027. The gradual transfer will occur over the next few months. TC Transcontinental will rely on its national integrated platform, mostly in its Vaughan, Ontario facility. This new business will require only minimal investment given TC Transcontinental Printing's scale, highly efficient and flexible platform, and its skilled workforce.

09:06 EST Electro-Sensors, Mobile X Global agree to terminate merger pact - Electro-Sensors and privately held Mobile X Global announced that the two companies have terminated the definitive merger agreement the parties entered into on June 10, 2022. A condition to closing of the merger transaction was the consummation of an equity financing with minimum gross proceeds of $20M, which the parties anticipated would be a PIPE investment. The financing necessary to consummate the merger was pursued but is not available due to difficult conditions in the financial markets, including the markets for PIPE investments. Electro-Sensors also announced that effective following the termination of the merger agreement, the Electro-Sensors board established a board special committee consisting of Chairman Joseph Marino, President David Klenk, and Audit Committee Chair Scott Gabbard, and authorized this committee to explore and pursue business development and other strategic alternatives for Electro-Sensors.

09:05 EST Finward Bancorp announces retirement of Executive Chairman Bochnowski - Finward Bancorp announced that David Bochnowski, the Executive Chairman of the Bancorp's Board of Directors, has informed the Board of his decision to retire as Executive Chairman and as a member of the Board, with his retirement to be effective as of June 30, 2023. The Board has appointed Benjamin Bochnowski, currently the Bancorp's President and Chief Executive Officer and a member of the Bancorp's Board of Directors, to succeed David Bochnowski as the Chairman of the Board. The appointment of Benjamin Bochnowski as Chairman is the result of the implementation of the Bancorp's normal succession planning process.

09:04 EST MoneyGram provides update on acquisition by MDP - MoneyGram provided an update on its agreement to be acquired by funds affiliated with Madison Dearborn Partners - MDP -. All regulatory approvals that are conditions to closing have been received except for one international money transmission regulatory approval to be issued by the Reserve Bank of India, or RBI. Since the company and MDP signed the Merger Agreement, the RBI issued a new Circular covering approval requirements related to Payment System Operators such as the company. As a result, the process has been taking longer than originally anticipated. Last week, the Central Government informed MoneyGram that it would take some additional time to complete its work in preparing its approval of the Transaction. Once this final international money transmission regulatory approval is obtained, the parties will engage in a financing marketing period which may last for as long as fifteen consecutive business days. Closing would occur within a matter of days after completing the marketing period. As a result, the parties have agreed to extend the End Date beyond February 14. The parties now expect to close the transaction either late in Q1 or early in Q2.

09:03 EST mdf Commerce enters partnership with Acumatica - mdf commerce announces a partnership agreement between its ecommerce solution, k-ecommerce, and Acumatica. Combined, the solutions create a comprehensive offering to SMB customers and expand the reach of mdf commerce's ecommerce solution. The k-ecommerce ERP-integrated ecommerce platform developed for Acumatica Cloud ERP users provides an all-in-one ecommerce, which includes a CMS, cloud hosting, as well as complete post-implementation service and training. Furthermore, k-ecommerce helps B2B businesses by delivering a PCI Level 1-compliant environment.

09:02 EST GSE Systems announces contract to work with Nuscale Power - GSE Solutions (GVP) announced a contract to work with NuScale Power (SMR) to develop a Hydrogen Plant Model for NuScale's VOYGR small modular reactor power plant simulator. GSE will provide the models, integration, and testing support to NuScale using its JProTM Dynamic Simulation Software.

08:55 EST Electro Sensors trading halted, news pending

08:49 EST California Water Service names Shawn Bunting general counsel - California Water Service Group (CWT) announced that Shawn Bunting, Esq. will join the company as Vice President, General Counsel and Corporate Secretary, effective March 1, 2023. He succeeds Lynn McGhee, who will retire after more than 19 years of service. Bunting comes to Group from American Water Works Company, Inc. (AWK), where he has served as a key member of the legal leadership team for nearly fifteen years.

08:45 EST CureVac announces data in older adults from COVID-19, flu mRNA vaccines - CureVac announced extended preliminary data from ongoing Phase 1 clinical programs in COVID-19 and seasonal flu conducted in collaboration with GSK. The newly reported data focus on older adult age groups in both indications. The data further support the decision to advance updated versions of the modified mRNA COVID-19 and flu vaccine constructs to the next stage of clinical testing in 2023. COVID-19 Program: Newly reported immunogenicity data from CV0501 in older adults are based on the fully recruited dose groups of 12, 25 and 50microgram, consisting of 10 subjects per dose. They show relevant titers of neutralizing antibodies beginning at the lowest tested dose. On day 29 at the 12microgram dose level, CV0501 generated a ratio of post-boost to pre-boost serum neutralizing titers against BA.1 of 13.3. While CV0501 encodes the Omicron BA.1 variant, a Phase 2 clinical study, expected to start later in 2023, will assess monovalent and/or bivalent vaccine candidates designed to target clinically relevant variants. Seasonal Flu Program: A single dose of Flu-SV-mRNA was assessed for safety and reactogenicity in older adults and was observed to be safe and well tolerated with no grade 3 adverse events in the 32 subjects who were administered the mRNA construct. Immunogenicity of Flu-SV-mRNA was assessed in parallel with a licensed seasonal flu vaccine comparator. Adjusted geometric mean hemagglutinin inhibition antibody titers elicited by Flu-SV-mRNA in older adults were approximately 2.3 times those elicited by the licensed vaccine comparator. In the same age group, the percentage of subjects achieving sero conversion was 89.7% for Flu-SV-mRNA and 56.2% for the licensed flu vaccine comparator. The vaccine candidate for future clinical development is expected to target all four flu virus strains currently recommended by the WHO for influenza vaccines. A Phase 1/2 study for multivalent vaccine candidates is expected to start around mid-2023.

08:41 EST Jaguar Health enters consulting agreement with Andrew Mulberg - Jaguar Health entered into a consulting agreement with Andrew Mulberg, M.D. to enhance the company's regulatory expertise. Dr. Mulberg was formerly Deputy Director for six years in the Division of Gastroenterology and Inborn Errors Products at the U.S. Food and Drug Administration.

08:40 EST Verses Technologies selected by 686 Technical Apparel to optimize supply chain - VERSES Technologies announced that it has been selected by 686 Technical Apparel to optimize the flow of its products within its distribution center. "We are pleased to help 686 better understand the dynamics in their warehouse and how to streamline operations," said James Hendrickson, President and GM of VERSES Enterprise. "I've been a fan of the 686 brand for a while so it's a treat to contribute to their internal logistics."

08:39 EST Sify becomes India's first NVIDIA DGX-ready data center colocation provider - Sify Technologies (SIFY) announced that it has been recognized as an NVIDIA (NVDA) DGX-Ready data center colocation provider. This makes Sify the first colocation provider in India to offer customers the option to host NVIDIA DGX A100 systems. With DGX systems, Sify will be able to provide its customers high-compute density, measurable performance and flexible infrastructure on many footprints across either private cloud deployments or colocation. Sify will offer data centers where customers can host NVIDIA DGX A100 systems for private cloud deployments. This includes NVIDIA DGX A100 platforms, NVIDIA AI and data science enterprise software and software development kits. "Artificial Intelligence and deep learning are transforming every industry. NVIDIA offers industry-leading compute density and performance, which provides Sify a unique advantage to offer complete NVIDIA DGX-powered colocation along with NVIDIA's leading enterprise AI and data science software," said Tirthankar Mitra, CEO at Sify Technologies.

08:38 EST Arrival appoints Igor Torgov as CEO - Arrival announces the appointment of Igor Torgov, former Arrival EVP of Digital, as CEO. The Board has unanimously voted in Igor to effect the planned restructuring of its business and to support Arrival's mission to master a radically more efficient New Method to design and produce electric vehicles. Igor Torgov's appointment will take effect from today, January 30, 2023. Igor joined Arrival in February 2020 and has led the development of multiple divisions at Arrival including Fintech, Commercialization, Business Systems, IT and Digital products over the last nearly three years.

08:37 EST Color Star Technology enters cooperation agreement with Quality Plus - Color Star Technology subsidiary Color Metaverse has entered into a strategic cooperation agreement with Quality Plus Biomedtech. In the future, the two companies plan to cooperate and assist with each other's business in areas including marketing, brand building, data sharing, and research and development. According to Quality Plus, it is a biotechnology company in Thailand that employs technology and medical techniques to develop safe and effective health and beauty products. Color Star has chosen to cooperate with them and plan use its platform, ColorWorld Metaverse to advertise and sell Quality Plus' cosmetology services and products, including health care products, makeup, and cosmetology procedures. Color World is a metaverse platform which features celebrity exclusives, virtual reality, and electronic commerce.

08:36 EST GeneDx made 'significant' contributions to GeneMatcher - In 2022, GeneDx, contributed a significant amount - 22% - of total candidate gene submissions to GeneMatcher, a platform that facilitates new disease gene discovery and enables connections between patients, clinicians and researchers by allowing individuals to submit and search genes of interest. "Our contributions to GeneMatcher are just one way we demonstrate our commitment to ending the diagnostic odyssey for patients," said Katherine Stueland, president and CEO of GeneDx, "By focusing on the bigger picture and utilizing our immense dataset and ability to interpret genetic findings at scale, we can continue to develop a more complete understanding of complex disease, improve diagnosis rates and help providers build effective treatment plans."

08:34 EST ToughBuilt announces launch of new handheld wrenches - ToughBuilt Industries announced the launch of more than 20 new SKUs into the Handheld Wrenches segment, including adjustable wrenches, construction wrenches and pipe wrenches. ToughBuilt Co-Founder and CEO Michael Panosian commented, "We are pleased to launch these 20 additional hand tool SKUs into the wrench segment and anticipate that they will create further revenue opportunities for the company." Panosian continued, "We believe these new product offerings will continue to build ToughBuilt's reputation for quality, and we intend to expand the company's products into additional segments throughout 2023 and the coming years."

08:33 EST BM Technologies appoints Raj Singh to board of directors - The Company announced the appointment of investment banking veteran Raj Singh to its Board of Directors effective January 27, 2023. Mr. Singh worked in the investment banking practice of Raymond James for more than 20 years, including most recently as Vice Chairman - Investment Banking from 2017 to 2023.

08:32 EST BM Technologies appoints Jamie Donahue as president, James Dullinger as CFO - On January 26, 2023, the Company elected Jamie Donahue, the Company's Executive Vice President and Chief Technology Officer, as the Company's President. Mr. Donahue has been in his current position with the Company since 2020. In his new position as President, Mr. Donahue will be responsible for leading the entire information technology, operations, product and program management, and sales teams as the Company pivots its strategy to ensure sustainable growth and profitability into the future as a leader in embedded finance and Banking-as-a-Service. Effective January 26, 2023, the Company transitioned Robert Ramsey, the Company's CFO, from that position to a new corporate development role. Concurrent with the transition of Mr. Ramsey, the Company elected James Dullinger, the Company's Chief Accounting Officer, to the additional position of CFO. Mr. Dullinger has been in his current position with the Company since March 2022.

08:29 EST Sesen Bio gets Nasdaq delisting notice, company sees Carisma deal as viable path - Sesen Bio announced that it has received notice from the Listing Qualifications Department of The Nasdaq Stock Market that, based upon the Company's non-compliance with the $1.00 bid price requirement for continued listing on The Nasdaq Capital Market, the Company's common stock is subject to delisting. The Company issued the following statement: "The receipt of this notice from Nasdaq underscores our belief that, without the pending merger with Carisma Therapeutics , the most likely and feasible path for Sesen Bio will be an exchange delisting of our common stock followed by the deregistration of our common stock from the SEC and a court-managed dissolution and liquidation. As noted previously, a court-managed dissolution and liquidation would be time consuming and expensive and would ultimately provide less value to Sesen Bio stockholders. Only approximately 60%-90% of Sesen Bio's cash balance, or approximately $0.40-$0.60 per share , and potentially less, would be available for an initial distribution, which may not be available for six months or more after an additional stockholder vote.

08:26 EST Shanghai Junshi announces approval for marketing of VV116 in China - Shanghai Junshi Biosciences announced that the National Medical Products Administration has conducted urgent review and approval under Special Examination and Approval of Drugs, and conditionally approved for marketing Deuremidevir Hydrobromide Tablets, an oral nucleoside analog anti-SARS-CoV-2 drug, for the treatment of adult patients with mild to moderate coronavirus disease 2019. VV116 is a new oral nucleoside analog antiviral drug, which can be non-covalently bound to the active center of RNA-dependent RNA polymerase of SARS-CoV-2 in the form of nucleoside triphosphate, directly inhibiting the activity of RdRp of the virus and blocking the replication of virus, thus realizing the antiviral effect. Preclinical studies have shown that VV116 exhibited significant antiviral effects against both the original COVID-19 strain and mutant strains, including Omicron, and exhibited no genetic toxicity.

08:25 EST Arrival trading halted, news pending

08:23 EST Patriot Battery Metals announces core assay results holes at CV5 Pegmatite - Patriot Battery Metals announces core assay results for the final ten drill holes completed at the CV5 Pegmatite from its 2022 drill campaign at its wholly owned Corvette Property, located in the James Bay Region of Quebec. The CV5 Pegmatite is located approximately 13.5 km south of the regional and all-weather Trans-Taiga Road and powerline infrastructure and is currently accessible by winter road. Blair Way, Company President, CEO and Director, comments: "The results herein conclude the release of core assays from the 2022 drill campaign at the CV5 Pegmatite and we could not be more thrilled with the results. We have exceeded all of our program objectives, expanding the known mineralized system from a few hundred metres along-strike in 2021, to at least 2.2 km in 2022, remaining open and demonstrating high-grades at both ends. We have just recently commenced our 2023 drill campaign and will continue to aggressively delineate what we believe will be a top tier lithium asset globally when fully defined."

08:22 EST IsoRay announces results of 2023 Annual Meeting of Stockholders - Isoray announced the results of its adjourned Fiscal 2023 Annual Meeting of Stockholders which was held on January 27, 2023. The stockholders approved Proposal One which amends the Company's Certificate of Incorporation to increase the total number of authorized shares of Common Stock to 750,000,000 shares. Proposal One, which required an affirmative vote of a majority of the outstanding common stock for passage, received 71,844,322 share votes in favor of the proposal which represents 50.55% of the total shares outstanding. The passage of Proposal One allows the Company to proceed with the proposed merger with Viewpoint Molecular Targeting, Inc. The Company anticipates completing the merger in the near future.

08:19 EST Immutep reports Q2 cash receipts $8,000 vs. $33,000 last quarter - Cash receipts from customers Q2 FY23 were $8k, compared to $33k in Q1 FY23. The Company received a A$986,286 cash rebate from the Australian Federal Government's R&D tax incentive program in relation to expenditure incurred on eligible R&D activities conducted in Australia in the 2021 fiscal year. The net cash used in G&A activities in the quarter was $734k compared to $595k in Q1 FY23. Payments to Related Parties, for the quarter includes $402k in payment of Non-Executive Director's fees and Executive Director's remuneration. The net cash used in R&D activities in the quarter was $5.87 million, compared to $7.17 million in Q1 FY23. The decrease was mainly due to a reduction in manufacturing activities during the quarter. Total net cash outflows used in operating activities in the quarter were $7.02 million compared to $6.35 million in Q1 FY23. Immutep's cash and cash equivalent balance at 31 December 2022 was approximately $68.38 million, giving the Company an expected cash reach based on current estimates to the end of FY24. Immutep will continue to manage its strong cash balance carefully as it pursues its overall clinical development strategy.

08:17 EST Brera Holdings announces international expansion strategy - Following its Nasdaq IPO last Friday, Brera Holdings announced its international strategy to simultaneously pursue expansion and licensing of the Brera FC brand in Eastern Europe, Africa, and South America, through the potential acquisition and, where appropriate, renaming of football teams with the objective of enhancing the players on these teams to place them on the professional transfer market and obtain prizes related to participation rights in UEFA. Brera Holdings CEO Sergio Scalpelli commented, "We are currently negotiating confidential deals for top division clubs in various European countries, starting from North Macedonia, while exploring opportunities primarily in Africa, but also in South America and other non-European countries. The choice of countries is based upon an in-depth analysis of the football, regulatory and economic parameters that are key to our business model." There is a Sizeable Market for European Football Competition Prizes. In the European countries in which Brera Holdings intends to operate, the Company intends to pursue the UEFA competitions market with at least three top-division teams. There are three UEFA competitions: The Champions League, or the CL, the Europa League, or the EL, and the Europa Conference League, or the Conference. A base participation prize is awarded to each of the 32 clubs that are admitted to the "group stage" of each UEFA competition.

08:16 EST Vaccitech appoints Pelletier as Chief Scientific Officer - Vaccitech (VACC) announced the appointment of Nadege Pelletier, Ph.D., as Chief Scientific Officer, CSO. Dr. Pelletier is stepping into the role formerly held by Tom Evans, Ph.D., who is retiring but will remain involved as a scientific consultant to the company. Dr. Pelletier joins Vaccitech from the Novartis Institutes for Biomedical Research and prior to that Roche (RHHBY) Pharma Research & Early Development, where she served as Project Leader in the fields of autoimmunity, inflammation and infectious diseases.

08:14 EST Aprea Therapeutics appoints John Hamill as Chief Financial Officer - Aprea Therapeutics announced the appointment of John Hamill as Chief Financial Officer. Hamill joins Aprea with more than 30 years of finance and accounting experience. Hamill joins Aprea with vast financial leadership experience in the pharmaceutical, biopharmaceutical, and clinical research sectors. The Company also announced that Scott Coiante will be stepping down as Chief Financial Officer to pursue other opportunities, but will remain with the Company through March 31, 2023 to ensure a smooth leadership transition.

08:13 EST Huntington Ingalls appoints Eric Chewning as EVP, Strategy & Development - HII announced that Eric Chewning, former chief of staff to the U.S. Secretary of Defense and deputy assistant secretary for industrial policy, is joining HII as executive vice president, Strategy & Development, reporting directly to HII President and CEO Chris Kastner. Chewning assumes the role on Jan. 30.

08:11 EST Global Crossing Airlines announces $5M financing - Global Crossing Airlines Group announced it has secured an up to $5.0 million loan with a key long-term investor to provide working capital and additional liquidity to support GlobalX's rapidly growing operations. The Loan is a six-month facility that will be funded in two tranches of $2.5M each. The first tranche will be advanced within one business day and the second tranche will be advanced after the Company delivers a draw down notice, but subject to the lender receiving internal approval for the second tranche. The Loan is unsecured, is not convertible, no warrants and will bear interest at the rate of 20% per annum, accruing monthly and payable upon maturity. The net proceeds of the Loan will be used to further the business objectives of the Company and to secure additional passenger and freighter Aircraft for charter operations that are expected to be delivered in Q1 2023.

08:09 EST scPharmaceuticals targets Feb 20 for commercial availability of FUROSCIX - scPharmaceuticals announced that the company is targeting February 20, 2023 as the date for commercial availability of FUROSCIX, a proprietary formulation of furosemide delivered via an On-Body Infusor for outpatient treatment of congestion due to fluid overload in adult patients with New York Heart Association Class II and Class III chronic heart failure. FUROSCIX is not indicated for emergency situations or in patients with acute pulmonary edema. FUROSCIX Infusor will deliver only an 80-mg dose. Management plans to provide a detailed update on the launch and other developments during its regularly scheduled fourth quarter 2022 earnings conference call and webcast in March.

08:08 EST Rev Group announces Mark Skonieczny as interim CEO - Rev Group (REVG) announced that Mark Skonieczny, CFO has been appointed interim CEO, effective January 27. Rod Rushing has stepped down as president and CEO and as a member of the board of directors. Skonieczny will join the REV Group board of directors effective immediately and remain CFO. Skonieczny will serve as Interim CEO until the role is permanently filled. Prior to joining REV Group, Skonieczny held positions as Vice President and Corporate Controller of Adient (ADNT).

08:06 EST Aethlon Medical signs agreement with NAMSA for Hemopurifier trials in cancer - Aethlon Medical has entered into an agreement with NAMSA, a MedTech Contract Research Organization offering global end-to-end development services to oversee the company's clinical trials investigating the Hemopurifier, Aethlon's immunotherapeutic device , for oncology indications. Pursuant to the agreement, NAMSA will manage Aethlon's study of the Hemopurifier for patients in the U.S. and Australia with various types of cancer tumors. It is anticipated the initial clinical trials will begin in Australia.

08:05 EST Decarbonization Plus Acquisition IV reopens redemption period - Decarbonization Plus Acquisition Corporation IV is reopening the period during which holders of DCRD's Class A ordinary shares may elect to redeem their DCRD Public Shares in connection with DCRD's previously announced business combination with Hammerhead Resources, pursuant to the Business Combination Agreement, dated as of September 25, 2022, by and among DCRD, Hammerhead, Hammerhead Energy Inc. and 2453729 Alberta ULC.

07:47 EST Baker Hughes, FFI sign MOU on green hydrogen, geothermal projects - Baker Hughes (BKR) announced a memorandum of understanding with Fortescue Future Industries (FSUGY) to jointly explore potential opportunities for the scale up and adoption of novel technology solutions for green hydrogen, green ammonia and geothermal projects. The companies see new pathways to accelerate the energy transition thanks to their respective expertise and portfolio of technologies on new projects. For hydrogen and ammonia development, the collaboration will leverage Baker Hughes' expertise and technology related to liquefaction and compression, turboexpanders and hydrogen-fueled turbines. For geothermal, Baker Hughes will provide its expertise for existing technologies in geothermal subsurface analysis, geothermal well services, emissions measurement, monitoring and carbon reinjection, as well as digital solutions for asset performance management and process optimization.

07:36 EST Irwin Naturals signs amended, restated LOI to acquire Braxia Scientific - Irwin Naturals entered into a non-binding amended and restated Letter of Intent for a business combination with Braxia Scientific. The LOI sets forth the material terms and conditions upon which Irwin will acquire all of the issued and outstanding common shares of Braxia. Under the terms of the LOI, Irwin is prepared to offer a purchase price per Braxia Share based upon a valuation of the outstanding Braxia Shares of $30,000,000 and a deemed value per subordinate voting share and/or proportionate voting share of Irwin equal to the greater of $3.00 and the volume weighted average trading price of Irwin Shares on the Canadian Securities Exchange for the 20 trading days immediately prior to the execution of the Arrangement Agreement. The purchase price would be payable on closing of the Proposed Transaction by the issuance of Consideration Shares to each holder of Braxia Shares. Based on the closing price of Irwin Shares and Braxia Shares on the CSE on January 25, 2023 of C$3.80 and C$0.05, respectively, the purchase price and exchange ratio imply a 315.72% premium to the price of Braxia Shares. The number of Consideration Shares will also be adjusted upward in the event that the total consideration received by holders of Braxia Shares is less than $30,000,000, to be determined at a specified period of time after the Closing Date and as set forth in the Arrangement Agreement. The final purchase price per Braxia Share and the exchange ratio will be set forth and determined at the time the Arrangement Agreement is executed. The LOI further provides that the Consideration Shares would be subject to a lock-up period and would be restricted from transfer or sale for a period of 6 months after the Closing Date. Insiders of Braxia would be subject to a Lock-Up period of 12 months from the Closing Date. Additionally, under the terms of the LOI and in connection with the Proposed Transaction, it is expected that the convertible securities of Braxia would, pursuant to the Arrangement Agreement, either remain outstanding in accordance with their terms or be exchanged for substantially similar securities of Irwin. The LOI is non-binding and there is no assurance that the Proposed Transaction will be completed as proposed. The completion of the Proposed Transaction is subject to, among other things completion of satisfactory due diligence by each of Braxia and Irwin; negotiation of and the entering into of a binding definitive Arrangement Agreement in connection with the Proposed Transaction; receipt of all required corporate approvals from the board of directors of Braxia and Irwin, respectively, and all regulatory and shareholder approvals, including the approval of the CSE and any required third-party consents: and Braxia having at least C$575,000 in working capital immediately before closing on the Closing Date.

07:33 EST Aleafia Health announces new international partner - Aleafia Health announces that it has signed a new European cannabis distribution partner, representing a one-year, approximately $1M contract, significantly bolstering the Company's record $1.2M year-to-date sales in its growing international channel. "This new announcement is very significant: it builds upon advancements made in August 2022 when the Company revealed a two-year $4.6 million European sales commitment and broadens our international reach," said Aleafia CEO Tricia Symmes. "The Company is involved in overseas markets because international success leverages both its products and brands, and the addressable European cannabis market is high potential, so this relationship provides another gateway into further European expansion in the medical and potential recreational markets."

07:26 EST Alterity Therapeutics announces publication of independent study of ATH434 - Alterity Therapeutics announced that a study recently published in the journal Neurotherapeutics demonstrated that its lead clinical asset, ATH434, was neuroprotective in a genetic model of Parkinson's disease Parkinson's is a progressive neurodegenerative disorder that causes slow or abnormal movements of the body and non-motor features that contribute significantly to morbidity and reduced quality of life. The publication, entitled "ATH434 Rescues Pre-motor Hyposmia in a Mouse Model of Parkinsonism" assessed the impact of ATH434 on motor and non-motor deficits in mice with genetically induced Parkinson's disease. Hyposmia, defined as reduced sensitivity to odor, is an early and common non-motor symptom of PD that precedes the typical motor symptoms by several years, occurring in approximately 90% of early-stage cases of PD. The study found that ATH434 prevented a loss of smell in the younger mice and rescued it in older mice. More importantly, the authors also demonstrated that ATH434 prevented the development of motor impairment in older animals, which was associated with a reduction in iron levels and preservation of neurons in the substantia nigra, the brain region affected in Parkinson's. These data support other studies indicating that ATH434 has a beneficial effect on the motor and non-motor symptoms in animal models of PD.

07:20 EST Alliance Resource Partners says well positioned to achieve record year in 2023 - "The supply driven energy crisis, Russia's invasion of Ukraine and the steep build of inflation disrupted energy prices and placed a new emphasis on energy security in 2022," commented Craft. "Europe's shift from Russian energy and U.S. and its allies' economic sanctions are lowering Russian supply to the world, changing global energy trade routes and energy markets for several years to come, if not permanently. U.S. natural gas and coal exports should benefit in 2023 and beyond. Due in part to this ongoing disruption, ARLP is well positioned to achieve another record year in 2023 by increasing production and sales by one to two million tons and relying on our highly committed coal contract book and a favorable market outlook to deliver 13.0 to 17.0% higher realized pricing compared to 2022," commented Craft. "Even though natural gas prices have fallen recently due to the warm winter experienced so far, coal prices remain elevated in anticipation of international demand firming throughout the year as China's economy reopens and as European markets look to replace 40 million tons of Russian coal imports received last year but unavailable this year. While the recent decline in natural gas prices are expected to impact our oil & gas royalties segment in the front half of the year, our coal segment should not be meaningfully affected due to our contracted position. In the back of this year and into 2024, we expect global economic activity will result in rising oil, gas and coal prices, and support our guidance. Craft concluded, "We are beginning to see the significant inflation experienced last year start to level off, however labor pressures and higher sales related expenses as a result of higher price realizations and coal sales volumes will continue to add to our costs in 2023. However, we expect favorable market forces and our current coal sales commitments will drive top line growth that should more than offset these inflationary pressures as margins are expected to improve across our business in 2023 versus the prior year."

07:15 EST Lifeist's Mikra begins commercial scale production of upgraded CELLF - Lifeist Wellness announced that its U.S. biosciences subsidiary Mikra Cellular Sciences has begun commercial scale production of a new and improved version of CELLF.

07:12 EST Alliance Resource Partners increases unit repurchase program to $100M - Alliance Resource Partners also announced that the board has authorized an increase to the previously established unit repurchase program, which had $6.5 of available capacity as of December 31, 2022. The expanded unit repurchase program authorizes ARLP to repurchase up to $100M of its outstanding limited partner common units.

07:10 EST TKB Critical Technologies 1 shareholders approve extension - TKB Critical Technologies 1 announced that in its extraordinary general meeting held, shareholders voted to approve an amendment to TKB's amended and restated memorandum and articles of association to extend the date that the Company has to consummate a business combination from January 29, 2023 to June 29, 2023. TKB's shareholders also approved a corresponding amendment to the Company's Investment Management Trust Agreement. The Extension was approved by approximately 99% of the votes cast at the meeting, representing approximately 82% of TKB's outstanding shares. An aggregate of 17,533,296 shares were validly redeemed in connection with the Extension. Following the Extension, after satisfaction of such redemptions, the balance in TKB's trust account will be approximately $55 million, approximately 24% of the total.

07:09 EST Voip-Pal.com announces U.S. WDTX lifted stay in its case against Amazon - VoIP-Pal.com (VPLM) announces the U.S. District Court for the Western District of Texas, WDTX, in VoIP-Pal's case versus Amazon.com (AMZN), et al., 6:20-cv-00272-ADA, has lifted the stay and scheduled a claim construction hearing for Friday February 3, 2023. The case asserts one of VoIP-Pal's RBR continuation patents U.S. Patent 10,218,606. Emil Malak, CEO of VoIP-Pal stated, "We are very happy to be resuming this case in Waco and to have the opportunity for our "606 patent to be tested on its merits. In the meantime we are continuing to move forward towards what we hope will be an eventual resolution. Patience is a virtue."

07:08 EST Xeris announces FDA grants orphan-drug exclusivity for Recorlev - Xeris Biopharma announced that the Food and Drug Administration FDA granted its subsidiary Xeris Pharmaceuticals orphan-drug exclusivity, ODE, for Recorlev or levoketoconazole, for the treatment of adult patients with endogenous Cushing's syndrome for whom surgery is not an option or has not been curative. As the first approval of levoketoconazole, Recorlev, for Cushing's syndrome, Xeris is entitled to seven years of orphan-drug market exclusivity from its FDA approval date of December 30, 2021. The FDA's Orphan Drug Designation program is designed to advance the development of drugs that treat a condition affecting 200,000 or fewer U.S. patients annually. This regulatory exclusivity is in addition to the patent exclusivity under Xeris' U.S. patents covering Recorlev and its therapeutic use, which extends to at least March 2040.

07:07 EST Beyond Cancer appoints Gavin Choy as Chief Operating Officer - Beyond Cancer, an affiliate of Beyond Air (XAIR), announced the appointment of Gavin Choy, PharmD as Chief Operating Officer. He brings more than 20 years of expertise to Beyond Cancer in the development of small molecules as well as immunotherapy in oncology with the successful management of multiple early first-in-human studies in the U.S. and Australia/New Zealand, and late-stage registrational clinical studies globally, as well as early access, and compassionate use programs. Dr. Choy most recently served as Chief Clinical Development Officer at GT Biopharma (GTBP).

07:06 EST Microbix Biosystems launches QAP to support Monkeypox testing - Microbix Biosystems announces that it is launching a new quality assessment product to support molecular diagnostic testing for the Non-Variola Orthopoxvirus, the cause of the cutaneous infection colloquially-known as "Monkeypox." From traditional low-level incidence in Central and Western Africa, incidence of Mpox surged meaningfully within many countries in 2022, leading to increased testing for this virus. However, transmission of this virus currently requires close or prolonged contact between individuals, limiting its pandemic potential. In collaboration with its PT/EQA partners, the Microbix Mpox QAP has now been validated for use across 11 leading MDx testing systems and multiple Lab Developed Tests, at 33 clinical laboratories in multiple European and Scandinavian nations. The Mpox QAP validation results may be presented by Microbix or its collaborators at a future scientific conference, in accordance with industry practices and standards. PT/EQA shipments of the Mpox QAP can now commence and Microbix expects material sales of this product starting in its current fiscal year.

07:05 EST Charles River acquires SAMDI Tech for $50M cash - Charles River Laboratories International announced that it has acquired SAMDI Tech provider of label-free high-throughput screening HTS solutions for drug discovery research. The acquisition marks the culmination of a partnership between the companies that began in 2018. Based in Chicago, Illinois, SAMDI Tech offers a proprietary mass spectrometry MS technology for high-throughput analysis of biochemical activities and affinity selection MS SAMDI ASMS for identifying binding interactions. The technology minimizes false positive results, reduces reagent requirements, and offers multiplexing capabilities without restricting assay conditions. These solutions are increasingly favored by clients to accelerate the timeline and reduce costs to identify a lead drug candidate, drive more effective research and high-quality scientific data, and enable clients to make critical go-no-go decisions earlier and advance their projects more efficiently. SAMDI Tech's comprehensive drug discovery solutions also include optical and radioactivity capabilities, cell-based assays, and an in-house collection of over a half million drug-like small molecules. James C. Foster, Chairman, President and Chief Executive Officer of Charles River Laboratories, commented, "The acquisition of SAMDI Tech's cutting-edge, high-throughput screening technology further strengthens Charles River's drug discovery capabilities and enhances our unique ability to serve as an integrated partner to support our clients' early-stage research. SAMDI Tech's platform combined with our premier, end-to-end drug discovery portfolio will generate better data and faster hit identification and is another step to accelerate our clients' drug discovery efforts. With over a decade of industry experience and the successful, existing partnership, we believe the addition of SAMDI Tech will continue to generate new business opportunities and we are pleased to welcome them to the Charles River family." The purchase price was $50M in cash for the remaining 80% ownership stake in SAMDI Tech that Charles River did not already own, subject to customary post-closing adjustments. Additional financial details were not disclosed as the transaction is not expected to have a material impact on Charles River's financial results in 2023. SAMDI Tech will become part of the Company's Discovery and Safety Assessment segment.

07:04 EST Genius Group board approves $37M spinoff of Entrepreneur Resorts - Genius Group Limited announces a plan approved by the Board for the spinoff of subsidiary Entrepreneur Resorts Ltd to create shareholder value. Entrepreneur Resorts Ltd is a public listed company on the Seychelles MERJ Stock Exchange with a share price of $2.75 and market cap of $37 million, with 97% of outstanding shares owned by Genius Group. The company was acquired in June 2020 in an all-share swap, with shareholders in ERL receiving shares in Genius Group. Entrepreneur Resorts Ltd operates a Bali resort, South Africa safari and co-working cafes in Bali and Singapore. The process of the spinoff is now underway following approval by the Board at Genius Group's Board Meeting on January 18, 2022. The spinoff will follow the Singapore legal process of a company restructure and capital reduction, and will be subject to shareholder approval and possibly a court order. If approved, it will result in all shareholders of Genius Group receiving an equal percentage of shares in ERL. The Board believes the spinoff will be of benefit to shareholders, as it will streamline and rationalize the group's operations into Genius Group Ltd with its Edtech focus, and Entrepreneur Resorts Ltd, with its hospitality focus, enabling the management teams of both companies to grow their respective business models most effectively.

07:03 EST C4 Therapeutics announces first patient dosed in Phase 1/2 trial of CFT1946 - C4 Therapeutics announced that the first patient has been dosed in its Phase 1/2 clinical trial of CFT1946, an orally bioavailable mutant-selective BiDAC degrader for the treatment of BRAF V600 mutant solid tumors. "Dosing the first patient in the CFT1946 Phase 1/2 clinical trial marks the first degrader to enter clinical development to target BRAF-driven cancers. Many of these patients are typically treated with BRAF inhibitors and have few treatment options once resistance emerges," said Adam Crystal, M.D., Ph.D., chief medical officer of C4 Therapeutics. "Preclinically, in in vivo models, CFT1946 has demonstrated deeper and more durable activity than approved BRAF inhibitors, and promising activity in the setting of resistance to BRAF inhibitors. We look forward to advancing CFT1946 for patients with BRAF V600 mutant cancers including non-small cell lung cancer, colorectal cancer, and melanoma." The Phase 1/2 clinical trial will primarily investigate safety, tolerability, and anti-tumor activity, with secondary and exploratory objectives to characterize the pharmacokinetic and pharmacodynamic profile of CFT1946.

07:03 EST Evoke Pharma says joint stipulation of dismissal filed in GIMOTI case - Evoke Pharma (EVOK) announced that a joint stipulation of dismissal has been filed in the GIMOTI patent infringement case in the United States District Court for the District of New Jersey. The filing of the stipulation arises from Teva Pharmaceuticals (TEVA) and Teva Pharmaceuticals USA's conversion from a Paragraph IV certification to a Paragraph III certification. A paragraph III Abbreviated New Drug Application is not eligible for approval until the last expiration date of current and potential future orange book listed patents for the reference listed drug in conjunction with appropriate FDA review. In addition, no future ANDA filer will be eligible to receive 180-day generic exclusivity for an ANDA that references GIMOTI. This first-to-file regulatory pathway is typically highly sought after by generic firms.

07:02 EST Destination XL appoints Pauker as Chief Operating Officer - Destination XL announced that Dara Pauker joined the organization as Chief Operating Officer on January 27, 2023. Pauker brings over 20 years of strategy and leadership experience, with a particular emphasis on growth initiatives, and has been working with the Company on a long-range strategic growth plan as a consultant since December, 2021. Reporting to Pauker will be the Chief Stores Officer, Chief Merchandising Officer, SVP Global Sourcing, and SVP Technology. Prior to joining DXL, Pauker operated her own consultancy, through which she has held many interim GM roles and advised public and private retail companies and investors in retail on a broad array of topics related to defining and executing growth strategy.

06:31 EST Babcock & Wilcox awarded $15M in contracts for waste-to-energy plants in UK - Babcock & Wilcox's B&W Environmental business segment has been awarded contracts totaling more than $14M to design and supply highly efficient dry cooling systems for waste-to-energy plants in the UK. B&W Environmental will supply SPIG air-cooled condensers for the projects, which provide significant environmental benefits and are well-suited for renewable energy applications such as waste-to-energy and biomass-fueled power plants. B&W Environmental offers design, engineering, manufacture and installation of dry cooling systems using only ambient air without any need for water, and its technologies are suitable for both renewable and thermal power plants.

06:07 EST Vera Therapeutics reports Phase 2 results of atacicept in IgA nephropathy - Vera Therapeutics announced results from a prespecified per-protocol - PP - analysis of the Phase 2b ORIGIN clinical trial of atacicept in patients with IgA nephropathy - IgAN - following announcement of topline results on January 3. ORIGIN is a clinical trial evaluating the efficacy and safety of atacicept in patients with IgAN who continue to have persistent proteinuria and remain at high risk of disease progression despite available ACE or ARB therapy. "This new analysis of proteinuria reduction in the ORIGIN Phase 2b clinical trial shows atacicept's ability to substantially reduce proteinuria, independent of changes in background regimens in the context of a multinational, randomized, placebo-controlled trial," said Jonathan Barratt, Professor of Renal Medicine, University of Leicester, U.K. CEO Marshall Fordyce said, "...Our team is well positioned to begin the pivotal trial in the first half of the year, subject to and following discussions with the FDA. With current timelines, we expect to announce Week 36 topline data from the Phase 3 clinical trial in the first half of 2025. Pending the data from the Phase 3 clinical trial, we expect to submit a BLA for atacicept to the FDA in the second half of 2025." In the PP analysis, at Week 24, the atacicept 150 mg dose group achieved a 41% mean reduction in proteinuria versus baseline and a 34% delta versus placebo. With interim data at Week 36, the atacicept 150 mg dose group achieved a 47% mean reduction in proteinuria from baseline and a 48% delta versus placebo2. Vera is continuing to rapidly advance atacicept into pivotal Phase 3 development, which is anticipated in the first half of 2023, subject to and following discussions with the FDA. Vera plans to prioritize and focus current resources on the advancement of atacicept in IgAN into a pivotal Phase 3 trial, extending cash runway to 4Q24.

05:49 EST Unilever appointes Hein Schumacher as new CEO, replacing Alan Jope - Unilever announced the appointment of Hein Schumacher as its new CEO, following an extensive, global search process. Hein will replace Alan Jope, who announced in September 2022 his intention to retire from Unilever. Hein is currently CEO of the global dairy and nutrition business Royal FrieslandCampina and became a Non-Executive Director of Unilever in October last year. He will begin as Unilever CEO on July 1, 2023, after a one-month handover period. Unilever Chairman Nils Andersen said: "We are delighted to welcome Hein as our new Chief Executive, after an extensive, global search process. Hein is a dynamic, values-driven business leader who has a diverse background of experiences and an excellent track record of delivery in the global consumer goods industry. He has exceptional strategic capabilities, proven operational effectiveness, and strong experience in both developed and developing markets. The Board looks forward to Hein realising the full potential of Unilever as a winning business which delivers long-term growth and value for all its stakeholders." Reference Link

05:45 EST Apple analyst Ming-Chi Kuo says company to release foldable iPad in 2024 - Apple plans to release a foldable iPad in 2024, featuring a carbon fiber kickstand, as well as an updated iPad mini, Apple analyst Ming-Chi Kuo said via Twitter on Monday. "I'm positive about the foldable iPad in 2024 and expect this new model will boost shipments and improve the product mix," he tweeted. Additionally, Kuo said: "I'm taking a cautious approach to iPad shipments for 2023, predicting a YoY decline of 10-15%." Reference Link

05:20 EST Regeneron, Sanofi announce EC expansion of Dupixent marketing authorization - Regeneron (REGN) and Sanofi (SNY) announced that the European Commission, or EC, expanded the marketing authorization for Dupixent in the European Union, or EU, to treat eosinophilic esophagitis, or EoE, in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy. EoE is a chronic, progressive inflammatory disease that damages the esophagus and prevents it from working properly. With this approval, Dupixent is the first and only targeted medicine specifically indicated to treat EoE in Europe and the U.S.

05:13 EST Philips to reduce workforce by additional 3,000 roles in 2023, 6,000 by 2025 - Philips presented its plan to create value with sustainable impact based on focused organic growth and scalable innovation, with improved execution as the key value driver. Starting at 10:00 am CET, the company will host a webcast with Philips CEO Roy Jakobs, CFO Abhijit Bhattacharya, and other Philips leaders. The presentation slide decks have been published here. Philips will change its operating model to end-to-end businesses with single accountability. They will be supported by lean central functions and strong customer facing organizations in the countries and regions. To this end, the company will right size the central functions, which will include organizational delayering and reallocating part of its corporate innovation activities to the businesses. In addition to the reduction of its workforce by 4,000 roles announced in October 2022, which is being implemented as planned, Philips will reduce its workforce by an additional 6,000 roles globally by 2025, of which 3,000 will be implemented in 2023 in line with the relevant local regulations and processes. Reflecting Philips' priorities, Philips has elevated the patient safety and quality function to the executive committee. Effective February 6, Steve C. de Baca has been appointed as chief patient safety & quality officer and member of Philips' executive committee reporting to CEO Roy Jakobs. He will bring more than 30 years of quality and regulatory affairs experience in the medical technology industry. Additionally, Jeff DiLullo has been promoted as the new chief market leader of Philips North America. Jeff brings more than 20 years of experience in sales, services and solutions delivery to drive growth in this very important region. Effective February 6, Jeff DiLullo will succeed Vitor Rocha, who has decided to leave Philips. Philips expects to announce the new leaders for its precision diagnosis business segment, previously led by Kees Wesdorp, who decided to leave Philips, as well as for its connected care business segment, in early 2023. These changes will result in renewal of the executive committee of 25% in early 2023.